HI-Bio
Website unreachable since Oct 30, 2026
Human Immunology Biosciences develops targeted therapies for immune-mediated diseases using advanced immunological techniques and biologics. The company addresses the unmet medical needs of patients suffering from conditions such as autoimmune disorders and chronic inflammatory diseases.
- Biotechnology
Funding
Raised to date
$1.5BRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Many individuals suffer from immune-mediated diseases, including autoimmune disorders and chronic inflammatory conditions, which often lack targeted and effective therapies. These diseases present significant unmet medical needs, impacting patients' quality of life and requiring innovative treatment approaches.
Solution
Human Immunology Biosciences (HI-Bio) develops targeted therapies designed to modulate the immune system and treat immune-mediated diseases. The company leverages advanced immunological techniques and biologics to create therapies that address the underlying causes of autoimmune and chronic inflammatory conditions. HI-Bio's approach aims to provide more effective and precise treatments, improving outcomes for patients with these challenging diseases.
Target Audience
The primary target audience includes patients suffering from autoimmune disorders and chronic inflammatory diseases, as well as healthcare providers seeking innovative treatment options for these conditions.
Features
- Development of targeted biologics for immune modulation
- Utilization of advanced immunological techniques in drug discovery
- Focus on addressing the root causes of immune-mediated diseases
- Pipeline of therapies for autoimmune disorders and chronic inflammatory conditions